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The risk of chemotherapy-induced infertility in male and female germ cell tumour (GCT) survivors is unclear, but may correlate with
cisplatin dose. Here, we examine a large series of GCT patients for the effect of chemotherapy on those attempting to have children.
Our GCT database was screened for nonseminomatous GCT patients who had (1) received POMB/ACE chemotherapy (cisplatin,
vincristine, methotrexate, bleomycin alternating with actinomycin D, cyclophosphamide and etoposide) and (2) stage I male GCT
patients who were untreated between 1977 and 1996. Fertility was assessed by questionnaire and medical records. A total of 64 of
153 treated and 35 of 115 untreated men attempted to have children. In all, 28% (18 out of 64) receiving POMB/ACE were
unsuccessful. Radiotherapy (six), atrophic remaining testis (one) or prior infertility (three) were implicated in 10 cases, so
chemotherapy-induced infertility may have occurred in only 11% (eight out of 64). Strikingly, 26% (nine out of 35) of untreated stage I
patients also failed to have children (three had radiotherapy, three prior infertility). Moreover, in treated men, no association was seen
between cisplatin dose and infertility. In contrast, radiotherapy significantly increased male infertility (P¼0.001). Of 28 treated women
who attempted to have children, 25% (seven out of 28) were unsuccessful. One previously had infertility and one subsequently had
successful IVF so chemotherapy-induced infertility potentially occurred in only 18% (five out of 28) and was not related to cisplatin
dose. In conclusion, the risk of chemotherapy-induced infertility is low in both male and female GCT patients and does not clearly
correlate with the cumulative cisplatin dose.
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Many young patients with cancers, including lymphomas,
leukaemias and germ cell tumours (GCTs), are cured with
multiagent chemotherapy. Indeed, we have previously reported
survival rates of 82% in men and 87.8% in women with GCTs at 5
and 3 years postchemotherapy, respectively (Bower et al, 1996,
1997). While short-term toxicities of chemotherapy are well
understood, some of the long-term toxicities such as the incidence
of infertility are poorly defined with quoted rates as high as 60% in
male and 40% in female subjects. This is partly because infertility
in patients with GCTs can be associated with multiple variables
including emotional distress (Jonker-Pool et al, 1997), the primary
tumour itself, the initial surgery to remove the affected testis or
ovary, any subsequent surgery, radiotherapy as well as with
chemotherapy (Schilsky, 1989).
Thus, even before chemotherapy, 22–63% of patients with
testicular GCTs have reduced sperm counts at diagnosis (Hart-
mann et al, 1999; Fossa and Kravdal, 2000). Indeed, abnormal
sperm counts may be associated with an increased risk of
developing GCTs (Jacobsen et al, 2000). Orchidectomy alone can
result in oligo or azoospermia (Petersen et al, 1998) and biopsy of
the ‘normal’ contra-lateral testis shows abnormal spermatogenesis
in up to 24% of cases (Berthelsen and Skakkebaek, 1983).
Subsequent retroperitoneal lymph node dissection (RPLND), if
performed, can also induce substantial infertility (Arai et al, 1997)
although with modern techniques this usually only occurs in 10–
15% of cases (Petersen et al, 1998). In women, the combined effects
of the tumour and surgery to remove ovarian GCTs may result in
pelvic scarring, which can contribute to infertility. However, exact
figures for pretreatment and surgically induced infertility in
women with ovarian GCTs are not available. Radiotherapy, when
used to treat male seminomas or its female equivalent, dysgermi-
nomas, can also contribute to infertility. Radiotherapy doses in
excess of 6–8 Gy in one fraction to the testes themselves will cause
irreversible azoospermia. Similarly, in women, ovarian failure will
inevitably result if the ovaries are irradiated. For men, radio-
therapy to the retroperitoneal lymph nodes can affect spermato-
genesis, even with testicular shielding. This appears to be dose
related as 100% of patients receiving o1Gy recovered spermato-
genesis, whereas only 60% recovered at doses 42Gy in one study
(Hansen et al, 1990).
During chemotherapy, 96% of men with GCTs become
azoospermic (Drasga et al, 1983) although most will recover
sperm counts following treatment (Lampe et al, 1997). Certain
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lchemotherapeutic agents are known to affect fertility more than
others. For GCTs, the most common sterilising drug is cisplatin,
but in studies of patients with Hodgkin’s disease or sarcoma,
mustine, busulphan, procarbazine, chlorambucil (4400mgm
 2),
and cyclophosphamide (47500mgm
 2) were the drugs most
likely to sterilise. It has been suggested that the threshold for
cisplatin-related infertility is 400mgm
 2 (Pont and Albrecht,
1997). Interestingly, cisplatin doses 4400mgm
 2 have also been
shown to correlate with the development of other long-term
toxicities in patients with GCTs (Bokemeyer et al, 1996; DeSantis
et al, 1999).
To complicate matters further, previous studies of treatment-
induced infertility have used various outcome measures of fertility,
including recovery of sperm counts and normal menstrual cycles.
However, women with regular periods and men with normal sperm
counts can be infertile (Hansen et al, 1991), and men with
oligospermia can father children (Stephenson et al, 1995). More-
over, some patients may be fertile but never wish or attempt to
have children. Clearly, the most distressing outcome for the
patients is where attempts to have children have failed. It has been
argued that since only one-third of patients wish to sire children
after treatment for GCTs, the group who try and fail to have
children are not representative (Pont and Albrecht, 1997). Never-
theless, infertility is a significant outcome only in patients who
wish for children. Provided follow-up times are long enough, the
method of assessing chemotherapy-induced infertility by assessing
the unfulfilled desire for children should detect all clinically
important events.
Here, we investigate rates of infertility (defined as the unfulfilled
wish for children) after a specific chemotherapy regime, POMB/
ACE (cisplatinum, vincristine, methotrexate, and bleomycin,
alternating with actinomycin D, cyclophosphamide, and etopo-
side) (Newlands et al, 1986) in long-term survivors of GCTs. We
compare the infertility rates with those seen in our stage I male
nonseminomatous germ cell tumours and with previously
published series. We also ask whether a relationship can be
demonstrated between cumulative dose of cisplatin and the risk of
infertility.
PATIENTS AND METHODS
The male and female GCT computer database at our institute was
screened to identify all patients who had received chemotherapy
between 1977 and 1996 or had stage I disease and had never
received chemotherapy. We identified 437 patients (366 men and
71 women) who had received POMB/ACE, the standard regimen
used to treat GCTs at our centre (Newlands et al, 1983; Bower et al,
1996; Bower et al, 1997), and 170 stage I male patients who were
untreated on our surveillance programme (Francis et al, 2000).
Only nonseminomatous germ cell tumours (NSGCT) were
included to reduce inclusion of male patients who had been
treated with radiotherapy. Moreover, patients who had: (a)
sterilising surgery (two men and 19 women); (b) a primary site
other than the gonads (23 men); (c) were too young or too old
(four men); (d) had ovarian dysgenesis with a 46XY karyotype
(one woman); (e) had ovarian ablation with radiotherapy (one
woman); or (f) were known to be homosexual (three patients) were
excluded from the study. A further 38 patients (all men) (10%)
were lost to follow-up and so were also not included. The patients
who were too young or too old were aged 88, 64, 64, and 18 years at
the time of the questionnaire. In all cases, although a questionnaire
was not sent, the patients were known to either have already
completed or not started their families.
Questionnaires were sent to all remaining patients enquiring
about fertility before and after chemotherapy, treatment or
investigations for infertility, impotence, and operations or
medications since the chemotherapy. Patients were also asked
about adoption. For the patients still under active follow-up,
information from the medical records was used to identify any
potential known cause, other than chemotherapy, including prior
investigation for infertility, surgery and radiotherapy.
Fertile and infertile GCT patients were compared for age, stage
and treatments including cisplatin chemotherapy doses. Signifi-
cance was assessed by w
2, Fisher’s exact tests and two-tailed t-tests
as indicated in the results tables using the statistical package SPSS
version 10.
In order to compare our results with previously published series,
we searched Medline using the search strings GERM CELL
TUMOUR, GERM, TERATOMA, INFERTILITY, FERTILITY,
CHEMOTHERAPY, AZOOSPERMIA, and CANCER. Bibliographies
of relevant studies and previously published reviews were also
searched.
RESULTS
A total of 437 patients (366 men and 71 women) were treated with
POMB/ACE for GCTs at Charing Cross Hospital between 1977 and
1996. In total, 335 (279 men and 56 women) were alive and well at
the time of the survey. Seven of the women had dysgerminomas,
but all the rest had NSGCTs.
Male GCTs
Questionnaires were sent out to 209 of the 279 treated males, the
remainder either being lost to follow-up or excluded because of
known infertility as described above in ‘Patients and Methods’. A
total of 159 questionnaires were returned (response rate 76%). Of
the questionnaires, 153 were assessable, and the mean follow-up
period for these patients was 11 years (range 5–24 years). A total
of 64 patients (42%) tried to father children after their treatment,
of whom 46 (72%) were successful and 18 (28%) were not.
Nonchemotherapy related causes of infertility were identified in
10 of the 18 patients who failed in their attempts to have children
(Table 1). These included radiotherapy (40Gy in 18 fractions to the
para-aortics/pelvic lymph nodes for NSCGTs all treated prior to
1980), atrophic remaining testis, low sperm counts or infertility
prior to chemotherapy. Of the remaining eight patients with
‘unexplained infertility’, three had fathered children before
receiving chemotherapy, but after treatment were unable to do
so due to low sperm counts. It is therefore likely that infertility in
these patients was induced by chemotherapy. The remaining five
patients failed to father children postchemotherapy but had not
had children or sperm counts pretreatment. Interestingly, one of
these five patients had a normal sperm count after chemotherapy
so failure to have a child may have been due to an infertility
problem with his partner. Thus, true chemotherapy-induced
infertility only occurred in up to 11% (seven out of 64) of the
patients who had attempted to father a child following POMB/ACE
treatment.
In total, seven of the 18 infertile patients had children by IVF
with donor sperm, and a further two had successful IVF with their
own sperm. Only one patient reported temporary difficulty with
Table 1 Causes of male infertility in POMB/ACE-treated patients
Total number of patients potentially fertile 153
Total number of patients who tried to have children 64
Total number of patients who were infertile 18
Explained infertility 10
Radiotherapy 6
Orchiectomy with contralateral atrophic testis 1
Low sperm counts prior to chemotherapy 2
Infertile before chemotherapy but not investigated 1
Unexplained infertility 8
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lejaculation. This patient had not undergone laparotomy or
RPLND.
Characteristics of the fertile and infertile groups were compared.
There was no significant difference in the average age of the two
groups at the time when treatment was started (26.5 and 26.3 years,
respectively), or in the proportion of men who had already had
children prior to diagnosis (Table 2). Table 3 shows that increasing
stage did not significantly influence the risk of being infertile.
However, dog-leg radiotherapy (4000rad in 18 fractions) to the
para-aortics and pelvic lymph nodes was markedly associated with
infertility (Po0.0001). In contrast, additional surgery, including
laparotomy or RPLND was only associated with a nonsignificant
increased risk of infertility (24 vs 43% for those not having vs
undergoing surgery; P¼0.72).
Since cisplatin has been implicated in the induction of infertility,
we examined the mean doses given to the fertile and infertile
groups. The fertile group received a mean cisplatin dose of
390mgm
 2 and the infertile group 407mgm
 2 (P¼0.65). If the
patients with pre-existing infertility, or radiotherapy were
excluded, the mean cisplatin doses were 390mgm
 2 in the fertile
group and 450mgm
 2 in the infertile group (P¼0.24). Previous
reports have suggested that patients receiving more than
400mgm
 2 of cisplatin are at greater risk of infertility. However,
in our series, 4400mgm
 2 cisplatin did not significantly increase
the risk of infertility even if patients who had had radiotherapy or
previous low sperm counts were excluded (Table 3). Cyclopho-
sphamide has also been implicated in inducing infertility,
particularly at doses above 7500mgm
 2. However, Table 4 shows
that the mean dose of cyclophosphamide received was only
1500mgm
 2 in the fertile and 1750mgm
 2 in the infertile groups
(a nonsignificant difference). Consequently, cyclophosphamide
may not have contributed to infertility in our patients.
There is clearly a concern that simply having a GCT can
contribute to infertility. To try and address this confounding
variable, we next examined the risk of infertility in our stage I
NSGCT patients who had been placed on surveillance and had
never required chemotherapy (Table 5). Of the 170 questionnaires
sent out, 69% were returned of which 114 were assessable. The
mean follow-up for these patients was 10.5 years (range 5–23
years) and was therefore broadly comparable to the POMB/ACE
treated patients. In all, 32% (37 out of 114) had no children before
their orchidectomy and had not tried to have children afterwards.
In all, 37% (42 out of 114) had children before their orchidectomy
but had not tried afterwards. Consequently, only 31% (35 out of
114) tried to have children following orchidectomy. Of these, 74%
were successful but nine (26%) tried and failed. Potential reasons
for failure to have children included radiotherapy (3), known low
sperm counts prior to orchidectomy (2) and contra-lateral
remaining atrophic testis (1). The remaining three patients had
not had children before orchidectomy and have subsequently been
unsuccessful having children. One has now stopped trying because
his wife has breast cancer and the other two men are currently
undergoing investigation with their partners for infertility. There-
fore, excluding the men who received radiotherapy, 17% (six out of
35) of stage I NSGCT patients were unable to have children
following their orchidectomy.
Female GCTs
In total, 35 women were alive and well and potentially fertile at the
time of the survey, and data were obtained on all of these. The
average follow-up time was 13.3 years. Seven of these patients were
too young or had not tried to conceive following chemotherapy. Of
the 28 remaining patients who tried to become pregnant, 75% (21)
succeeded without added intervention, resulting in a total of 36
Table 2 Male age in the fertile and infertile groups at diagnosis:





Fathered children prior to
diagnosis
18 (39%) 4 (22%) 0.2
Didnot father children prior to
diagnosis
28 (61%) 14 (78%)
Age at time of diagnosis 26.5 26.3 0.99
P-value determined by w
2.









III or IV 33% (8/24) P¼0.93
Unknown 0% (0/4)
Given radiotherapy 100% (6/6) Po0.0001
No radiotherapy 21% (12/58)
Had a laparotomy/RPLND 43% (6/14) P¼0.19
No laparotomy 24% (12/50)
Including all causes of infertility
o400mgm
 2 cisplatin 26% (12/46)
4400mgm
 2 cisplatin 29% (5/17) P¼0.72
Excluding nonchemotherapy causes of infertility
o400mgm
 2 cisplatin 13% (5/39)
4400mgm
 2 cisplatin 21% (3/14) P¼0.42
P-values determined by Fisher’s exact or w
2 tests.
Table 4 Mean doses of chemotherapy in the fertile and infertile groups
Fertile Infertile
Infertile with no cause apart
from chemotherapy
P-value (CI) comparing third
with first columns
Mean dose of cisplatin 390mgm
 2 (n¼45) 407mgm
 2 (n¼18) 450mgm
 2 (n¼8) P¼0.24 ( 161.4 to 41.3)
Mean dose of cyclo-phosphamide 1500mgm
 2 (n¼45) 1750mgm
 2 (n¼18) 1875mgm
2 (n¼8) NS
P-value determined by t-test. NS¼nonsignificant.
Table 5 Causes of male infertility in nontreated stage 1 patients
Total number of patients potentially fertile 114
Total number of patients who tried to have children 35
Total number of patients who were infertile 9
Explained infertility 6
Radiotherapy 3
Orchidectomy with contralateral atrophic testis 1
Low sperm counts prior to orchidectomy 2
Unexplained infertility 3
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lpregnancies (see Table 6). A total of 28 pregnancies were carried to
term, with only one reported fetal abnormality (an atrial septal
defect). There were five miscarriages and two terminations, and
one patient was pregnant at the time of the survey. Therefore, 25%
of patients (seven out of 28) had an unfulfilled desire for children.
However, one of these was already known to have fertility
problems and had undergone unsuccessful IVF before chemother-
apy. Another had successful IVF following chemotherapy. Of the
remaining five patients, three were still having regular periods and
two were known to be menopausal postchemotherapy. Conse-
quently, only up to five patients (18%) are likely to have been
rendered infertile by the chemotherapy.
The characteristics of the fertile and infertile groups were
compared. The mean age of the two groups was equivalent (20
years). There was a small but nonsignificant trend towards higher
doses of chemotherapy in the infertile patients. The fertile group
received a mean cisplatin dose of 380.9mgm
 2 and the infertile
group received a mean dose of 424.3mgm
 2 (P¼0.65 95% CI of
difference –102.6 to 65.0) (Table 7). In keeping with the male
GCT results, there was no significant difference in fertility rates
between women receiving above and below 400mgm
 2 cisplatin
(Table 8).
Radiotherapy and laparotomy rates have not been compared for
the women, because the numbers of patients are much smaller.
One patient received 46Gy to the pelvis and was not included in
the analysis as this dose is almost certain to cause ovarian ablation.
DISCUSSION
As more patients are cured of their tumours, the long-term
consequences of the therapies used become increasingly impor-
tant. Preservation of fertility is a major issue for patients with
GCTs, which are often diagnosed in individuals who have not yet
started their families. Previous studies have identified that surgery
(RPLND or laparotomy), radiotherapy, bulk of disease and
chemotherapy (Rustin et al, 1987) can all contribute to subsequent
infertility. However, the overall rates of infertility vary widely and
can be as high as 60% in men and 40% in women following
treatment for their GCTs (see Tables 9 and 10). The reasons for
this wide variation are likely due to small patient numbers,
differences in inclusion/exclusion criteria and the methods used to
assess fertility including sperm counts and menstruation vs
children sired.
To our knowledge, the current study represents one of the
largest series concerning infertility postchemotherapy for GCTs.
We have found that in those patients who desire a child
postchemotherapy, 28% of men and 25% of women have been
unsuccessful. Of these, chemotherapy could be implicated as the
probable cause in only 11% of men and 18% of women.
Approximately 10% of couples in the general population will be
infertile (Abma et al, 1997). Since patients with GCTs have a higher
incidence of infertility than the general population, even before
receiving treatment, it is likely that chemotherapy makes little
difference to infertility in men and only a marginal difference to
women. In keeping with this notion, we found that 17% of male
stage I GCT patients were unable to father children despite not
having chemotherapy, radiotherapy, or RPLND following their
orchidectomy. Moreover, it is of interest that in the only case–
control study comparing fertility in stage I male GCT patients who
either did or did not receive two cycles of cisplatin containing
chemotherapy, there was no excess of infertility in the treated
group of patients (Pont et al, 1996). Of course, one could argue
that the dose of cisplatin received in the Pont study was too low to
induce infertility. However, we have not been able to show any
dose-dependent correlation with risk of infertility in our study
despite the findings of others (Pont and Albrecht, 1997). Never-
Table 6 Summary of fertility in female GCT patients
Total number of potentially fertile patients 35
Number who tried to have children 28
Number who became pregnant 21
Number of pregnancies 36
Number of live births 28
Number of miscarriages 5
Number of terminations 2
Number of malformations 1 ASD
Number who were infertile 7
IVF attempted 2 (1 success)
Table 7 Comparison of the mean cisplatin and cyclophosphamide doses
given to women with GCTs who were subsequently found to be fertile or
infertile























aOne patient who received carboplatin instead of cisplatin was excluded in each
group. P-value determined by t-test. NS¼nonsignificant.
Table 8 Comparison of infertility rates in women receiving more or less
then 400mgm
 2 of cisplatin (P¼1.00)
Fertile Infertile % infertile P-value
o400mgm
 2 cisplatin 11 3 21% 1.00
4400mgm
 2 cisplatin 8 3 27%
P determined by Fisher’s exact test.














Roth (Roth et al, 1988) 229 147 6 PVB7A
b N/A 24 N/A
c
Hansen (Hansen et al, 1990) 177 28 49 Various 8 3 5 (63%)
Bisset (Bissett et al, 1990) 120 74 11 Various N/A 18 N/A
Pont (Pont et al, 1996) 42 25 0 2 PEB
a N/A 7 N/A
Hartman (Hartmann et al, 1999) 124 98 20 Various 40 21 19 (48%)
Petersen (Petersen and Hansen, 1999) 22 22 0 PVB 16 9 7 (44%)
Bohlen (Bohlen et al, 2001) 59 49 0 PVB or BEP N/A 16 5
This study 366 153 0 POMB-ACE 64 46 18 (28%)
aPEB/BEP¼cisplatin, etoposide, and bleomycin.
bPVB7A¼cisplatin, vincristine, and bleomycin with or without adriamycin.
cN/A¼data not available from published article.
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ltheless, we did find that patients receiving above 900mgm
 2
of cisplatin lost their fertility (data not shown). Moreover, in
women treated for gestational trophoblastic tumours with etopo-
side, methotrexate, actinomycin D alternating with cyclopho-
sphamide and vincristine (EMA/CO), we similarly failed to find
any evidence of reduced fertility postchemotherapy (Woolas et al,
1998).
So, why are our findings different from those previously
reported? Many of the studies include patients with variable
histological types, some of the patient groups are selected for stage
of disease, and chemotherapy regimes as well as surgical and
radiotherapeutic techniques vary widely. In particular, patients
with seminomas are more likely to have received radiotherapy.
Some investigators assumed that married patients desired children
and unmarried patients did not (Wu et al, 1991). In contrast, the
data presented here rely almost entirely on fertility rates as
reported by patients. However, this is clearly subjective with
patient’s enthusiasm for filling in and returning questionnaires
potentially being affected by their fertility status. In addition, the
incidence of nonpaternity is unknown in our male GCT patients.
Finally, all studies were observational including our own except
Pont et al (1996), which was a case–control study.
A number of important questions remain unanswered. New
drugs, specifically the taxanes, are being used to treat GCTs
(Motzer et al, 1994). Very little is known about the long-term
effects of these. We mention that seven of the infertile male
patients’ partners were treated successfully with IVF and donor
sperm. In addition, a further two couples were treated successfully
with IVF and their own sperm. The impact of new techniques such
as intracytoplasmic sperm injection (ICSI) on couples who are
sub-fertile after chemotherapy is not yet known. Indeed, the
relative success of IVF is not known in couples who have received
chemotherapy, although sperm storage prior to treatment is
routinely offered.
We conclude that rates of infertility after treatment for GCTs in
our series are 28% in men and 25% in women. The contribution of
chemotherapy to this is likely to be very small. Moreover, we could
not confirm a significant relationship between dose of cisplatin
received and chance of infertility. Nevertheless, we still recom-
mend that all male GCT patients are offered sperm storage and
when the technology is available, equivalent oocyte storage for
female GCT is performed prior to chemotherapy. While there are
many theoretical reasons why chemotherapy may induce inferti-
lity, it would appear that the risks of this occurring are small.
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